Moderna Shares Hit Four Year High on Cancer Vaccine Initiative

Moderna shares climbed more than 14% on Friday, October 9, reaching their highest level since January 2022, after The New York Times reported plans for a US initiative to accelerate cancer vaccine research. The National Institutes of Health (NIH) expects the public-private program to launch in December, potentially creating new opportunities for biotechnology companies developing cancer treatments. The initiative aims to speed up research by bringing together government researchers, pharmaceutical and biotechnology companies, nonprofit organizations, advocacy groups, and patients.

According to The New York Times, the effort will seek to replicate aspects of the collaboration that helped accelerate COVID-19 vaccine development. Initial research is expected to target pancreatic, liver, and colorectal cancers, as well as pediatric tumors. The announcement also lifted other biotechnology stocks, with Pfizer, BioNTech, and Merck advancing alongside Moderna.

Novavax shares rose 15% on Friday, according to Yahoo Finance.

Stacey Adam, a senior clinical officer at the NIH's foundation, told The New York Times that the program is expected to begin in December. The initiative follows a similar effort launched in the United Kingdom in 2024 called the Cancer Vaccine Launch Pad.

The research push comes as advances in artificial intelligence and messenger RNA technology expand opportunities to develop treatments tailored to individual patients. Unlike preventive vaccines designed to protect against infections, therapeutic cancer vaccines aim to help the immune system recognize and attack cancer cells in people who already have the disease. Moderna has established a position in the emerging field through its collaboration with Merck on an investigational mRNA-based treatment for melanoma. On August 19, the companies announced results showing that intismeran, administered with Merck's Keytruda, increased the time before cancer returned or spread in patients with high-risk melanoma.

The companies' findings followed positive results from a late-stage clinical trial, according to Yahoo Finance. The developments have drawn investor attention to Moderna's cancer treatment pipeline as pharmaceutical companies explore ways to advance personalized therapies. Moderna's stock performance has been particularly strong in 2026. Yahoo Finance reported that shares had gained 662% year to date as of its October 9 coverage, reflecting a substantial rally before the latest advance.

However, the proposed national research program remains a planned initiative rather than an established treatment breakthrough. Its expected December launch would bring together multiple organizations to accelerate research across several cancer types, while Moderna's investigational therapy continues to depend on clinical development and further evaluation.